Compare PEGA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEGA | RYTM |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | 1996 | 2017 |
| Metric | PEGA | RYTM |
|---|---|---|
| Price | $34.79 | $92.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | $40.00 | ★ $138.59 |
| AVG Volume (30 Days) | ★ 1.8M | 616.9K |
| Earning Date | 10-20-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 91.89 | 28.34 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $682,695,000.00 | N/A |
| Revenue This Year | $6.76 | $65.10 |
| Revenue Next Year | $8.40 | $78.21 |
| P/E Ratio | $132.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.10 | $74.50 |
| 52 Week High | $68.10 | $122.20 |
| Indicator | PEGA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 30.67 |
| Support Level | $34.49 | $82.43 |
| Resistance Level | $35.49 | $99.50 |
| Average True Range (ATR) | 1.22 | 3.52 |
| MACD | -0.20 | -0.36 |
| Stochastic Oscillator | 53.14 | 28.55 |
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.